You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.
Altmetrics
Downloads
121
Views
52
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
No. | Authors and year of publication | Country | Number of patients | Period of time analysed | The type of primary cancer/pre-cancer lesion | Median age of participants | Number of AIN/AC | Increased risk | Risk of bias |
---|---|---|---|---|---|---|---|---|---|
1. | Acevedo-Fontánez et al. (2018) [17] | Puerto-Rico | 9,489 | 1987-2013 | 8,039 CC 1,378 VC 773 VaC |
46 CC, 70 VC, 67 VaC |
14 AC after CC 3 AC after VC 1 AC after VaC |
AC after CC: SIR= 1.8 (95% Cl: 0.9- 3.4) AC after VC & VaC: SIR= 2.9 (95% Cl: 0.8-7.5) |
L |
2. | Chaturvedi et al. (2007) [18] | USA | 27,466 | 1973–2001 | 27,466 CC* | 48.6 | NI | AC after CC: SIR= 3.12; 95% CI = 1.88-4.88 | L |
3. | Ebisch et al. (2017) [19] | Netherlands | 89,018 | 1990-2015 | 89,018 CIN 3 | 36 | 73 AC 80 AIN 3 |
AC after CIN 3: SIR= 3.85 (95% CI: 2.32-6.37) AIN 3 after CIN 3: SIR= 6.68 (95% CI: 3.64- 12.25) |
L |
4. | Edgren et al. (2007) [20] | Sweden | 125,292 | 1968-2004 | 125,292 CIN 3 | 35 | 131 AC | AC after CIN 3: SIR= 4.68 (95% Cl: 3.87- 5.62) | L |
5. | ElNaggar et al. (2013) [21] | USA | 272 | 2006-2010 | CIN 1 29 CIN 2 16 CIN 3/CIS 41 VIN 1 46 VIN 2 16 VIN 3/CIS 69 VaIN 1 34 VaIN 2 13 VaIN 3/CIS 8 =272 |
39 | 64 AIN (36 stage 1, 6 stage 2, 22 stage 3) | 48 (36.4%) had VIN, 10 (18.2%) had VaIN, and 13 (14.4%) had CIN. | H |
6. | Evans et al. (2003) [22] | England | 81,124 | 1960-1999 | 59,519 CIN 3 21,605 CC |
NI | 23 AC after CIN 3 18 AC after CC |
AC after CIN 3: SIR= 5.9 AC after CC: SIR= 6.3 |
L |
7. | Gaudet et al. (2014) [23] | Canada | 54,320 | 1985-2005 | 54,320 CIN 2 and CIN 3** |
35 | 4 AC after CIN 2 16 AC after CIN 3 |
AC after CIN 2: SIR= 0.89 (95% Cl: 0.09- 3.35) AC after CIN 3: SIR= 2.28 (95% Cl: 0.71- 5.42) |
L |
8. | Hemminki et al. (2001) [24] | Sweden | 17,234 | 1958-1996 | 17,234 CC | NI | 16 AC | AC after CC: SIR= 4.22 (95% Cl: 2.41-6.55) | L |
9. | Hemminki et al. (2000) [25] | Sweden | 135,386 | 1958-1996 | 117,830 CIN 3 17,556 CC |
NI | 68 AC after CIN 3 17 AC after CC |
AC after CIN 3: SIR= 3.75 (95% Cl: 2.91-4.69) AC after CC: SIR= 3.92 (95% Cl: 2.28-6.00) |
L |
10. | Heráclio et al. (2018) [26] | Brazil | 324 | 2008-2009 | 200 CIN 1, 97 CIN 2 or CIN 3, 27 CC |
33 | 37 AIN | AIN after CIN 1: IR= 7% AIN after CIN 2/3: IR= 18.5% |
L |
11. | Jakobsson et al. (2011) [27] | Finland | 26,876 | 1987–2006 | 26,876 CIN (unknown grade) | NI | 3 AC | AC after CIN: SIR= 3.56 (95% Cl: 0.73-10.4) | H |
12. | Jiménez et al. (2009) [28] | Canada | 674 | 1992-2005 | 7 CC, 3 VaC and 1 VC | 61 | 674 AC | AC after HPV-RGD: OR= 10.5 (95% CI: 3.6-30.3) AC after CC: OR= 6.84 (95% CI: 2.16-21.61) |
H |
13. | Kalliala et al. (2005) [29] | Finland | 7,564 | 1974-2003 | 2,446 CIN 1 1,543 CIN 2 1,334 CIN 3 2,241 CIN “not otherwise specified” |
NI | 3 AC | AC after CIN: SIR= 5.7 (95% Cl: 1.2 to 17.0) | L |
14. | Matsuo et al. (2018) [30] | USA | 79,050 | 1973-2013 | 79,050 CC | 63 | 49 AC | 10-, 20-, 30-year cumulative incidence for AC after CC: 0.04%, 0.16%, and 0.38% | H |
15. | Neumann et al. (2016) [31] | French | 4,808 | 1989-2007 | 4,234 CC 339 VC 235 VaC |
NI | 5 AC after CC 1 AC after VC 0 AC after VaC |
AC after CC: SIR= 5.42 (95% Cl: 1.75–12.64) AC after VC: SIR= 11.7 (95% Cl: 0.15–65.51) |
L |
16. | Pan et al. (2019) [32] | Scotland | NI | 1989-2015 | 69,714 CIN 3 | 30 | 37 AC after CIN 3 | AC after CIN 3: SIR= 2.6 (95% Cl: 1.9–3.6) | L |
17. | Papatla et al. (2019) [33] | USA | 21,060 | 1973-2014 | 21,060 CC | 61.73 | 17 AC | AC after CC: SIR= 2.20 (95% Cl: 1.28-3.52) | L |
18. | Preti et al. (2020) [34] | Italy | 3,184 | 1992-2004 | 3,184 CIN 2 or 3 | NI | 1 AC | AC after CIN 2 or 3: SIR= 1.8 (95% Cl: 0.04–10.0) | H |
19. | Rabkin et al. (1992) [35] | USA | 25,295 | 1935-1988 | 25,295 CC | NI | 12 AC | AC after CC: SIR= 4.6 (95% Cl: 2.4-8.1) | H |
20. | Saleem et al. (2011) [36] | USA | 189,206 | 1973-2007 | 124,075 CIN 3 6,792 VIN 3 1,463 VaIN 3 43,669 CC 9,950 VC 3,257 VaC |
NI | 255 AC | AC after CIN 3: SIR= 16.4 (95% CI: 13.7–19.2) AC after CC: SIR= 6.2 (95% CI: 4.1– 8.7) AC after VIN 3: SIR= 22.2 (95% CI: 16.7–28.4) AC after VC: SIR= 17.4 (95% CI: 11.5–24.4) AC after VaIN 3: SIR= 7.6 (95% CI: 2.4–15.6) AC after VaC: SIR= 1.8 (95% CI: 0.2–5.3) |
L |
21. | Sand et al. (2016) [37] | Denmark | 156,290 | 1978-2012 | 52,135 CIN 2 104,155 CIN 3 |
33.8 for CIN 2 34.0 for CIN 3 |
32 AC after CIN 2 125 AC after CIN 3 |
AC after CIN 2: SIR= 2.9 (2.0–4.1) AC after CIN 3: SIR= 4.2 (3.4–5.0) |
L |
22. | Suk et al. (2018) [38] | USA | 52,589 | 1973-2014 | 44,011 CC 6,905 VC 1,673 VaC |
63 for CC, 61 for VC, 95 for VaC |
34 AC after CC 31 AC after VC 1 AC after VaC |
AC after CC: SIR= 2.3 (95% CI: 1.6-3.2) AC after VC: SIR=13.2 (95% CI: 8.9-18.7) AC after VaC: SIR= 2.3 (95% CI: 0.1-12.8) |
L |
23. | Tatti et al. (2012) [39] | Argentina | 481 | 2005-2011 | 121 CIN 1 114 CIN 2/3 188 VIN 1 39 VIN 2/3 70 VaIN 1 22 VaIN 2/3 |
35 | 28 AIN 2/3 106 AIN 1 |
No info (AIN after CIN 2/3 comparted to AIN after CIN 1: OR= 1.91) |
H |
24. | Tomassi et al. (2018) [40] | USA | 221,511 | 2005-2015 | 1,168 CC 15,711 CIN 2/3 109,893 CIN 1 94,739 genital warts |
63.8 | 1 AC after CC 5 AC after CIN 2/3 14 AC after CIN 1 14 AC after genital wards |
AC after CC: IR= 0.09% AC after CIN 2/3: IR= 0.03% AC after CIN 1: IR= 0.01% AC after genital wards: IR= 0.01% |
H |
25. | Wang et al. (2020) [41] | USA | 56,127 | 2000-2015 | 46,550 CC 7,855 VC 1,722 VaC |
NI | 50 AC after CC 9 AC after VC 1 AC after VaC |
AC after CC: SIR= 1.63 (95% Cl: 1.21- 2.14) AC after VC: SIR= 1.10 (95% Cl: 0.50-2.09) AC after VaC: SIR= 0.62 (95% Cl: 0.01- 3.47) |
L |
AC | anal cancer |
AIN | anal intraepithelial neoplasia |
CC | cervical cancer |
CIN | cervical intraepithelial neoplasia |
Cl | confidence level |
HPV | human papillomavirus |
HPV-RGD | HPV-related gynecological diseases |
IR | incidence risk |
OR | odds ratio |
PY | person-years |
SD | standard deviation |
SIR | standardized incidence ratio |
VaC | vaginal cancer |
VaIN | vaginal intraepithelial neoplasia |
VIN | vulvar intraepithelial neoplasia |
VC | vulvar cancer |
No. | Authors and year of publication | Number of secondary AIN or AC / number of primary HPV-RGD | Person-years | Incidence rate of AIN or AC | IR per 100,000 person-years | Comment |
---|---|---|---|---|---|---|
1. | Acevedo-Fontánez et al. (2018) [17] | 10 AC / 8,039 CC 3 AC / 1,378 VC 1 AC / 773 VaC |
119,617 14,631 6,554 |
0.124% 0.217% 0.129% |
8.36 20.5 15.26 |
|
2. | Chaturvedi et al. (2007) [18] | - | - | - | - | No information about the number of AC cases. |
3. | Ebisch et al. (2017) [19] | 73 AC / 89,018 CIN 3 80 AIN 3 / 89,018 CIN 3 |
1,261,804 1,261,804 |
0.082% 0.090% |
5.79 6.34 |
|
4. | Edgren et al. (2007) [20] | 131 AC / 125,292 CIN 3 | 2 193 409 | 0.105% | 5.97 | |
5. | ElNaggar et al. (2013) [21] | 13 AIN / 90 CIN 48 AIN / 132 VIN 10 AIN / 55 VaIN |
- - - |
14.4% 36.4% 18.2% |
- - - |
1 AIN out of 3 CC but not included because of to small number of cases |
6. | Evans et al. (2003) [22] | 23 AC / 59,519 CIN 3 18 AC / 21,605 CC |
477,069 145,621 |
0.039% 0.083% |
4.82 12.36 |
|
7. | Gaudet et al. (2014) [23] | 20 AC / 54,320 CIN 2 and CIN 3 | 545,945 | 0.037% | 3.66 | |
8. | Hemminki et al. (2001) [24] | 16 AC / 17,234 CC | - | 0.093% | - | |
9. | Hemminki et al. (2000) [25] | 68 AC / 117,830 CIN 3 17 AC / 17,556 CC |
- | 0.058% 0.097% |
- | |
10. | Heráclio et al. (2018) [26] | 14 AIN / 200 CIN 1 23 AIN / 124 CIN 2 and 3 |
- | 7% 18.5% |
- | |
11. | Jakobsson et al. (2011) [27] | 3 AC / 26,876 CIN | 226,510 | 0.011% | 1.32 | |
12. | Jiménez et al. (2009) [28] | - | - | - | - | No information about the total number of CC, VC or VaC cases. |
13. | Kalliala et al. (2005) [29] | 3 AC / 7,564 CIN | 97,556 | 0.040% | 3.08 | |
14. | Matsuo et al. (2018) [30] | 49 AC / 79,050 CC | - | 0.062% | - | |
15. | Neumann et al. (2016) [31] | 3 AC / 4,234 CC 1 AC / 339 VC |
28,122 1,533 |
0.071% 0.295% |
10.67 65,23 |
|
16. | Pan et al. (2019) [32] | 37 AC / 69,714 CIN 3 | 893,622 | 0.053% | 4.14 | |
17. | Papatla et al. (2019) [33] | 17 AC / 21,060 CC | - | 0.081% | - | |
18. | Preti et al. (2020) [34] | 1 AC / 3,184 CIN 2 and 3 | 20,022 | 0.031% | 4.99 | |
19. | Rabkin et al. (1992) [35] | 12 AC / 25,295 CC | 156,838 | 0.047% | 7.65 | |
20. | Saleem et al. (2011) [36] | 137 AC / 124,075 CIN 3 28 AC / 43,669 CC 5 AC / 1,463 VaIN 3 2 AC / 3,257 VaC 55 AC / 6,792 VIN 3 28 AC / 9,950 VC |
- | 0.110% 0.064% 0.342% 0.061% 0.810% 0.281% |
- | |
21. | Sand et al. (2016) [37] | 32 AC / 52,135 CIN 2 125 AC / 104,155 CIN 3 |
597,467 1,529,564 |
0.061% 0.120% |
5.36 8.17 |
|
22. | Suk et al. (2018) [38] | 34 AC / 44,011 CC 31 AC / 6,905 VC 1 AC / 1,673 VaC |
473,820 48,373 9,057 |
0.077% 0.449% 0.060% |
7.18 64.09 11.04 |
|
23. | Tatti et al. (2012) [39] | 20 AIN / 114 CIN 2 and 3 35 AIN / 121 CIN 1 18 AIN / 39 VIN 7 AIN / 22 VaIN 2 and 3 27 AIN / 70 VaIN 1 |
- | 17.544% 28.926% 46.154% 31.818% 38.571% |
- | Results without dividing AIN into HSIL (AIN 2/3) and LSIL (AIN 1). |
24. | Tomassi et al. (2018) [40] | 1 AC / 1,168 CC 14 AC / 109,893 CIN 1 5 AC / 15,711 CIN 2 and 3 |
10,359 708,690 114,031 |
0.086% 0.013% 0.032% |
9.65 12.74 4.38 |
|
25. | Wang et al. (2020) [41] | 50 AC / 46,550 CC 9 AC / 7,855 VC 1 AC / 1,722 VaC |
- - - |
0.107% 0.115% 0.058% |
7.6 2.1 8.3 |
No information about PY. IR per 100,000 PY as provided by the authors of the publication. |
Type of HPV-related gynecological disease | Risk of AC mean SIR (range)1 | Risk of AC mean IR2 | Risk of AC mean IR per 100,000 PY3 | Risk of AIN mean SIR (range)1 | Risk of AIN mean IR2 | Risk of AIN mean IR per 100,000 PY3 |
---|---|---|---|---|---|---|
Cervical cancer | 3.6 (1.6-6.3) | 0.084% | 9.73 | |||
Vulvar cancer | 10.8 (1.1-17.4) | 0.286% | 37.98 | |||
Vaginal cancer | 1.6 (0.6-2.3) | 0.059% | 11.78 | |||
CIN 3 | 5.6 (2.3-16.4) | 0.075% | 5.78 | 6.7 (3.64- 12.25) | 6.34 | |
CIN(1-3) | 4.6 (0.9-16.4) | 0.030% | 5.37 | 16.45% | ||
VIN 3 | 0.810% | |||||
VIN(1-3) | 36.4% | |||||
VaIN 3 | 0.342% | |||||
VaIN(1-3) | 18.2% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
supplementary.docx (52.70KB )
Submitted:
13 May 2023
Posted:
15 May 2023
You are already at the latest version
A peer-reviewed article of this preprint also exists.
supplementary.docx (52.70KB )
This version is not peer-reviewed
Submitted:
13 May 2023
Posted:
15 May 2023
You are already at the latest version
No. | Authors and year of publication | Country | Number of patients | Period of time analysed | The type of primary cancer/pre-cancer lesion | Median age of participants | Number of AIN/AC | Increased risk | Risk of bias |
---|---|---|---|---|---|---|---|---|---|
1. | Acevedo-Fontánez et al. (2018) [17] | Puerto-Rico | 9,489 | 1987-2013 | 8,039 CC 1,378 VC 773 VaC |
46 CC, 70 VC, 67 VaC |
14 AC after CC 3 AC after VC 1 AC after VaC |
AC after CC: SIR= 1.8 (95% Cl: 0.9- 3.4) AC after VC & VaC: SIR= 2.9 (95% Cl: 0.8-7.5) |
L |
2. | Chaturvedi et al. (2007) [18] | USA | 27,466 | 1973–2001 | 27,466 CC* | 48.6 | NI | AC after CC: SIR= 3.12; 95% CI = 1.88-4.88 | L |
3. | Ebisch et al. (2017) [19] | Netherlands | 89,018 | 1990-2015 | 89,018 CIN 3 | 36 | 73 AC 80 AIN 3 |
AC after CIN 3: SIR= 3.85 (95% CI: 2.32-6.37) AIN 3 after CIN 3: SIR= 6.68 (95% CI: 3.64- 12.25) |
L |
4. | Edgren et al. (2007) [20] | Sweden | 125,292 | 1968-2004 | 125,292 CIN 3 | 35 | 131 AC | AC after CIN 3: SIR= 4.68 (95% Cl: 3.87- 5.62) | L |
5. | ElNaggar et al. (2013) [21] | USA | 272 | 2006-2010 | CIN 1 29 CIN 2 16 CIN 3/CIS 41 VIN 1 46 VIN 2 16 VIN 3/CIS 69 VaIN 1 34 VaIN 2 13 VaIN 3/CIS 8 =272 |
39 | 64 AIN (36 stage 1, 6 stage 2, 22 stage 3) | 48 (36.4%) had VIN, 10 (18.2%) had VaIN, and 13 (14.4%) had CIN. | H |
6. | Evans et al. (2003) [22] | England | 81,124 | 1960-1999 | 59,519 CIN 3 21,605 CC |
NI | 23 AC after CIN 3 18 AC after CC |
AC after CIN 3: SIR= 5.9 AC after CC: SIR= 6.3 |
L |
7. | Gaudet et al. (2014) [23] | Canada | 54,320 | 1985-2005 | 54,320 CIN 2 and CIN 3** |
35 | 4 AC after CIN 2 16 AC after CIN 3 |
AC after CIN 2: SIR= 0.89 (95% Cl: 0.09- 3.35) AC after CIN 3: SIR= 2.28 (95% Cl: 0.71- 5.42) |
L |
8. | Hemminki et al. (2001) [24] | Sweden | 17,234 | 1958-1996 | 17,234 CC | NI | 16 AC | AC after CC: SIR= 4.22 (95% Cl: 2.41-6.55) | L |
9. | Hemminki et al. (2000) [25] | Sweden | 135,386 | 1958-1996 | 117,830 CIN 3 17,556 CC |
NI | 68 AC after CIN 3 17 AC after CC |
AC after CIN 3: SIR= 3.75 (95% Cl: 2.91-4.69) AC after CC: SIR= 3.92 (95% Cl: 2.28-6.00) |
L |
10. | Heráclio et al. (2018) [26] | Brazil | 324 | 2008-2009 | 200 CIN 1, 97 CIN 2 or CIN 3, 27 CC |
33 | 37 AIN | AIN after CIN 1: IR= 7% AIN after CIN 2/3: IR= 18.5% |
L |
11. | Jakobsson et al. (2011) [27] | Finland | 26,876 | 1987–2006 | 26,876 CIN (unknown grade) | NI | 3 AC | AC after CIN: SIR= 3.56 (95% Cl: 0.73-10.4) | H |
12. | Jiménez et al. (2009) [28] | Canada | 674 | 1992-2005 | 7 CC, 3 VaC and 1 VC | 61 | 674 AC | AC after HPV-RGD: OR= 10.5 (95% CI: 3.6-30.3) AC after CC: OR= 6.84 (95% CI: 2.16-21.61) |
H |
13. | Kalliala et al. (2005) [29] | Finland | 7,564 | 1974-2003 | 2,446 CIN 1 1,543 CIN 2 1,334 CIN 3 2,241 CIN “not otherwise specified” |
NI | 3 AC | AC after CIN: SIR= 5.7 (95% Cl: 1.2 to 17.0) | L |
14. | Matsuo et al. (2018) [30] | USA | 79,050 | 1973-2013 | 79,050 CC | 63 | 49 AC | 10-, 20-, 30-year cumulative incidence for AC after CC: 0.04%, 0.16%, and 0.38% | H |
15. | Neumann et al. (2016) [31] | French | 4,808 | 1989-2007 | 4,234 CC 339 VC 235 VaC |
NI | 5 AC after CC 1 AC after VC 0 AC after VaC |
AC after CC: SIR= 5.42 (95% Cl: 1.75–12.64) AC after VC: SIR= 11.7 (95% Cl: 0.15–65.51) |
L |
16. | Pan et al. (2019) [32] | Scotland | NI | 1989-2015 | 69,714 CIN 3 | 30 | 37 AC after CIN 3 | AC after CIN 3: SIR= 2.6 (95% Cl: 1.9–3.6) | L |
17. | Papatla et al. (2019) [33] | USA | 21,060 | 1973-2014 | 21,060 CC | 61.73 | 17 AC | AC after CC: SIR= 2.20 (95% Cl: 1.28-3.52) | L |
18. | Preti et al. (2020) [34] | Italy | 3,184 | 1992-2004 | 3,184 CIN 2 or 3 | NI | 1 AC | AC after CIN 2 or 3: SIR= 1.8 (95% Cl: 0.04–10.0) | H |
19. | Rabkin et al. (1992) [35] | USA | 25,295 | 1935-1988 | 25,295 CC | NI | 12 AC | AC after CC: SIR= 4.6 (95% Cl: 2.4-8.1) | H |
20. | Saleem et al. (2011) [36] | USA | 189,206 | 1973-2007 | 124,075 CIN 3 6,792 VIN 3 1,463 VaIN 3 43,669 CC 9,950 VC 3,257 VaC |
NI | 255 AC | AC after CIN 3: SIR= 16.4 (95% CI: 13.7–19.2) AC after CC: SIR= 6.2 (95% CI: 4.1– 8.7) AC after VIN 3: SIR= 22.2 (95% CI: 16.7–28.4) AC after VC: SIR= 17.4 (95% CI: 11.5–24.4) AC after VaIN 3: SIR= 7.6 (95% CI: 2.4–15.6) AC after VaC: SIR= 1.8 (95% CI: 0.2–5.3) |
L |
21. | Sand et al. (2016) [37] | Denmark | 156,290 | 1978-2012 | 52,135 CIN 2 104,155 CIN 3 |
33.8 for CIN 2 34.0 for CIN 3 |
32 AC after CIN 2 125 AC after CIN 3 |
AC after CIN 2: SIR= 2.9 (2.0–4.1) AC after CIN 3: SIR= 4.2 (3.4–5.0) |
L |
22. | Suk et al. (2018) [38] | USA | 52,589 | 1973-2014 | 44,011 CC 6,905 VC 1,673 VaC |
63 for CC, 61 for VC, 95 for VaC |
34 AC after CC 31 AC after VC 1 AC after VaC |
AC after CC: SIR= 2.3 (95% CI: 1.6-3.2) AC after VC: SIR=13.2 (95% CI: 8.9-18.7) AC after VaC: SIR= 2.3 (95% CI: 0.1-12.8) |
L |
23. | Tatti et al. (2012) [39] | Argentina | 481 | 2005-2011 | 121 CIN 1 114 CIN 2/3 188 VIN 1 39 VIN 2/3 70 VaIN 1 22 VaIN 2/3 |
35 | 28 AIN 2/3 106 AIN 1 |
No info (AIN after CIN 2/3 comparted to AIN after CIN 1: OR= 1.91) |
H |
24. | Tomassi et al. (2018) [40] | USA | 221,511 | 2005-2015 | 1,168 CC 15,711 CIN 2/3 109,893 CIN 1 94,739 genital warts |
63.8 | 1 AC after CC 5 AC after CIN 2/3 14 AC after CIN 1 14 AC after genital wards |
AC after CC: IR= 0.09% AC after CIN 2/3: IR= 0.03% AC after CIN 1: IR= 0.01% AC after genital wards: IR= 0.01% |
H |
25. | Wang et al. (2020) [41] | USA | 56,127 | 2000-2015 | 46,550 CC 7,855 VC 1,722 VaC |
NI | 50 AC after CC 9 AC after VC 1 AC after VaC |
AC after CC: SIR= 1.63 (95% Cl: 1.21- 2.14) AC after VC: SIR= 1.10 (95% Cl: 0.50-2.09) AC after VaC: SIR= 0.62 (95% Cl: 0.01- 3.47) |
L |
AC | anal cancer |
AIN | anal intraepithelial neoplasia |
CC | cervical cancer |
CIN | cervical intraepithelial neoplasia |
Cl | confidence level |
HPV | human papillomavirus |
HPV-RGD | HPV-related gynecological diseases |
IR | incidence risk |
OR | odds ratio |
PY | person-years |
SD | standard deviation |
SIR | standardized incidence ratio |
VaC | vaginal cancer |
VaIN | vaginal intraepithelial neoplasia |
VIN | vulvar intraepithelial neoplasia |
VC | vulvar cancer |
No. | Authors and year of publication | Number of secondary AIN or AC / number of primary HPV-RGD | Person-years | Incidence rate of AIN or AC | IR per 100,000 person-years | Comment |
---|---|---|---|---|---|---|
1. | Acevedo-Fontánez et al. (2018) [17] | 10 AC / 8,039 CC 3 AC / 1,378 VC 1 AC / 773 VaC |
119,617 14,631 6,554 |
0.124% 0.217% 0.129% |
8.36 20.5 15.26 |
|
2. | Chaturvedi et al. (2007) [18] | - | - | - | - | No information about the number of AC cases. |
3. | Ebisch et al. (2017) [19] | 73 AC / 89,018 CIN 3 80 AIN 3 / 89,018 CIN 3 |
1,261,804 1,261,804 |
0.082% 0.090% |
5.79 6.34 |
|
4. | Edgren et al. (2007) [20] | 131 AC / 125,292 CIN 3 | 2 193 409 | 0.105% | 5.97 | |
5. | ElNaggar et al. (2013) [21] | 13 AIN / 90 CIN 48 AIN / 132 VIN 10 AIN / 55 VaIN |
- - - |
14.4% 36.4% 18.2% |
- - - |
1 AIN out of 3 CC but not included because of to small number of cases |
6. | Evans et al. (2003) [22] | 23 AC / 59,519 CIN 3 18 AC / 21,605 CC |
477,069 145,621 |
0.039% 0.083% |
4.82 12.36 |
|
7. | Gaudet et al. (2014) [23] | 20 AC / 54,320 CIN 2 and CIN 3 | 545,945 | 0.037% | 3.66 | |
8. | Hemminki et al. (2001) [24] | 16 AC / 17,234 CC | - | 0.093% | - | |
9. | Hemminki et al. (2000) [25] | 68 AC / 117,830 CIN 3 17 AC / 17,556 CC |
- | 0.058% 0.097% |
- | |
10. | Heráclio et al. (2018) [26] | 14 AIN / 200 CIN 1 23 AIN / 124 CIN 2 and 3 |
- | 7% 18.5% |
- | |
11. | Jakobsson et al. (2011) [27] | 3 AC / 26,876 CIN | 226,510 | 0.011% | 1.32 | |
12. | Jiménez et al. (2009) [28] | - | - | - | - | No information about the total number of CC, VC or VaC cases. |
13. | Kalliala et al. (2005) [29] | 3 AC / 7,564 CIN | 97,556 | 0.040% | 3.08 | |
14. | Matsuo et al. (2018) [30] | 49 AC / 79,050 CC | - | 0.062% | - | |
15. | Neumann et al. (2016) [31] | 3 AC / 4,234 CC 1 AC / 339 VC |
28,122 1,533 |
0.071% 0.295% |
10.67 65,23 |
|
16. | Pan et al. (2019) [32] | 37 AC / 69,714 CIN 3 | 893,622 | 0.053% | 4.14 | |
17. | Papatla et al. (2019) [33] | 17 AC / 21,060 CC | - | 0.081% | - | |
18. | Preti et al. (2020) [34] | 1 AC / 3,184 CIN 2 and 3 | 20,022 | 0.031% | 4.99 | |
19. | Rabkin et al. (1992) [35] | 12 AC / 25,295 CC | 156,838 | 0.047% | 7.65 | |
20. | Saleem et al. (2011) [36] | 137 AC / 124,075 CIN 3 28 AC / 43,669 CC 5 AC / 1,463 VaIN 3 2 AC / 3,257 VaC 55 AC / 6,792 VIN 3 28 AC / 9,950 VC |
- | 0.110% 0.064% 0.342% 0.061% 0.810% 0.281% |
- | |
21. | Sand et al. (2016) [37] | 32 AC / 52,135 CIN 2 125 AC / 104,155 CIN 3 |
597,467 1,529,564 |
0.061% 0.120% |
5.36 8.17 |
|
22. | Suk et al. (2018) [38] | 34 AC / 44,011 CC 31 AC / 6,905 VC 1 AC / 1,673 VaC |
473,820 48,373 9,057 |
0.077% 0.449% 0.060% |
7.18 64.09 11.04 |
|
23. | Tatti et al. (2012) [39] | 20 AIN / 114 CIN 2 and 3 35 AIN / 121 CIN 1 18 AIN / 39 VIN 7 AIN / 22 VaIN 2 and 3 27 AIN / 70 VaIN 1 |
- | 17.544% 28.926% 46.154% 31.818% 38.571% |
- | Results without dividing AIN into HSIL (AIN 2/3) and LSIL (AIN 1). |
24. | Tomassi et al. (2018) [40] | 1 AC / 1,168 CC 14 AC / 109,893 CIN 1 5 AC / 15,711 CIN 2 and 3 |
10,359 708,690 114,031 |
0.086% 0.013% 0.032% |
9.65 12.74 4.38 |
|
25. | Wang et al. (2020) [41] | 50 AC / 46,550 CC 9 AC / 7,855 VC 1 AC / 1,722 VaC |
- - - |
0.107% 0.115% 0.058% |
7.6 2.1 8.3 |
No information about PY. IR per 100,000 PY as provided by the authors of the publication. |
Type of HPV-related gynecological disease | Risk of AC mean SIR (range)1 | Risk of AC mean IR2 | Risk of AC mean IR per 100,000 PY3 | Risk of AIN mean SIR (range)1 | Risk of AIN mean IR2 | Risk of AIN mean IR per 100,000 PY3 |
---|---|---|---|---|---|---|
Cervical cancer | 3.6 (1.6-6.3) | 0.084% | 9.73 | |||
Vulvar cancer | 10.8 (1.1-17.4) | 0.286% | 37.98 | |||
Vaginal cancer | 1.6 (0.6-2.3) | 0.059% | 11.78 | |||
CIN 3 | 5.6 (2.3-16.4) | 0.075% | 5.78 | 6.7 (3.64- 12.25) | 6.34 | |
CIN(1-3) | 4.6 (0.9-16.4) | 0.030% | 5.37 | 16.45% | ||
VIN 3 | 0.810% | |||||
VIN(1-3) | 36.4% | |||||
VaIN 3 | 0.342% | |||||
VaIN(1-3) | 18.2% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Leticia Muñoz-Hernando
et al.
JPM,
2022
Marta Pino
et al.
Cancers,
2023
Anna Iacobone
et al.
Diagnostics,
2023
© 2024 MDPI (Basel, Switzerland) unless otherwise stated